{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:25:57Z","timestamp":1793676357609,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Copenhagen University","id":[{"id":"https:\/\/ror.org\/035b05819","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      International guidelines recommend assessment for bone metastases in patients with high-risk prostate cancer (PC) and those with unfavourable intermediate-risk disease. These recommendations are largely based on studies using planar bone scintigraphy. We aimed to assess the diagnostic accuracy of [\n                      <jats:sup>18<\/jats:sup>\n                      F]sodium fluoride ([\n                      <jats:sup>18<\/jats:sup>\n                      F]NaF) PET\/CT in newly diagnosed PC. We also evaluated the clinical utility of routine bone imaging in patients with unfavourable intermediate-risk disease and International Society of Urological Pathology grade group (ISUP GG) 3.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective single-center study included 734 consecutive patients with newly diagnosed PC who underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]NaF PET\/CT for primary staging. Patients were classified according to the current European Association of Urology risk classification, with the intermediate-risk subgroup restricted to patients with ISUP GG 3. All scan reports were retrospectively reviewed, and patient-level findings regarding bone metastases were validated against a reference standard based on follow-up imaging and clinical data. Sensitivity, specificity, and predictive values were calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 734 patients, 607 (83%) had high-risk disease and 127 (17%) had intermediate-risk disease with ISUP GG 3. Overall, bone metastases were detected in 225 patients (31%). Among high-risk patients, 224 (37%) had bone metastases, whereas only 1 of 127 intermediate-risk patients (0.8%) had bone metastases on [\n                      <jats:sup>18<\/jats:sup>\n                      F]NaF PET\/CT. Follow-up identified one additional potential false-negative case in the intermediate-risk group. Among patients with a conclusive reference standard (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009689), sensitivity and specificity were 0.90 and 0.99, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]NaF PET\/CT demonstrates high diagnostic accuracy for the detection of bone metastases in newly diagnosed PC. However, given the very low prevalence of bone metastases, its clinical utility in patients with unfavourable intermediate-risk disease and ISUP GG 3 appears limited.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08148-y","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:10:24Z","timestamp":1788577824000},"page":"8488-8496","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of bone metastases on [18F]NaF PET\/CT in 734 patients with newly diagnosed prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-8094","authenticated-orcid":false,"given":"Claus","family":"Madsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle D.","family":"Zacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Bisbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Fugl\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"\u00d8stergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"key":"8148_CR1","unstructured":"Cornford P, Tilki D, van den Bergh RCN, Eberli D, Fonteyne V, Gandaglia G, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer [Internet]. 2026 Mar. https:\/\/uroweb.org\/guidelines\/prostate-cancer. Accessed 16 Apr 2026."},{"key":"8148_CR2","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.2967\/jnumed.116.189183","volume":"58","author":"J L\u00f6fgren","year":"2017","unstructured":"L\u00f6fgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, et al. A prospective study comparing 99m Tc-HDP planar bone scintigraphy and whole-body SPECT\/CT with 18F-fluoride PET\/CT and 18F-fluoride PET\/MRI for diagnosing bone metastases. J Nucl Med. 2017;58:1778\u201385. https:\/\/doi.org\/10.2967\/jnumed.116.189183.","journal-title":"J Nucl Med"},{"key":"8148_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00345-017-2096-3","volume":"36","author":"M Wondergem","year":"2018","unstructured":"Wondergem M, Zant FM, Knol RJJ, Burgers AMG, Bos SD, de Jong IJ, et al. 99mTc-HDP bone scintigraphy and 18F-sodium fluoride PET\/CT in primary staging of patients with prostate cancer. World J Urol. 2018;36:27\u201334. https:\/\/doi.org\/10.1007\/s00345-017-2096-3.","journal-title":"World J Urol"},{"key":"8148_CR4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.clgc.2018.07.009","volume":"16","author":"T Lengana","year":"2018","unstructured":"Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, et al. 68Ga-PSMA PET\/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer. 2018;16:392\u2013401. https:\/\/doi.org\/10.1016\/j.clgc.2018.07.009.","journal-title":"Clin Genitourin Cancer"},{"key":"8148_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2013.05.059","volume":"64","author":"MM Siddiqui","year":"2013","unstructured":"Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, et al. Magnetic resonance imaging\/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64:713\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2013.05.059.","journal-title":"Eur Urol"},{"key":"8148_CR6","unstructured":"Spratt DE, An Y, Bitting R, Chapin B, Cheng HH, Cho SY, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026 [Internet]. www.nccn.org. Accessed 16 Apr 2026."},{"key":"8148_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2967\/jnumed.124.268275","volume":"66","author":"C Madsen","year":"2025","unstructured":"Madsen C, Fugl\u00f8 D, Pedersen M, Broholm R, \u00d8stergren PB, Bisbjerg R, et al. Prospective head-to-head comparison of 18F-PSMA PET\/CT and 18F-NaF PET\/CT for assessing bone metastases in 160 patients with newly diagnosed high-risk prostate cancer. J Nucl Med. 2025;66:223\u20139. https:\/\/doi.org\/10.2967\/jnumed.124.268275.","journal-title":"J Nucl Med"},{"key":"8148_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2967\/JNUMED.119.232686","volume":"61","author":"HD Zacho","year":"2020","unstructured":"Zacho HD, Fonager RF, Nielsen JB, Haarmark C, Hendel HW, Johansen MB, et al. Observer agreement and accuracy of 18F-sodium fluoride PET\/CT in the diagnosis of bone metastases in prostate cancer. J Nucl Med. 2020;61:344\u20139. https:\/\/doi.org\/10.2967\/JNUMED.119.232686.","journal-title":"J Nucl Med"},{"key":"8148_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.eururo.2009.12.023","volume":"57","author":"A Briganti","year":"2010","unstructured":"Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol. 2010;57:551\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2009.12.023.","journal-title":"Eur Urol"},{"key":"8148_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-017-0229-z","author":"Y Lin","year":"2017","unstructured":"Lin Y, Mao Q, Chen B, Wang L, Liu B, Zheng X, et al. When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? A retrospective study. BMC Urol. 2017. https:\/\/doi.org\/10.1186\/s12894-017-0229-z.","journal-title":"BMC Urol"},{"key":"8148_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/RLU.0000000000000291","volume":"39","author":"HD Zacho","year":"2014","unstructured":"Zacho HD, Barsi T, Mortensen JC, Mogensen MK, Bertelsen H, Josephsen N, et al. Prospective multicenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer. Clin Nucl Med. 2014;39:26\u201331. https:\/\/doi.org\/10.1097\/RLU.0000000000000291.","journal-title":"Clin Nucl Med"},{"key":"8148_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/nejmoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382:917\u201328. https:\/\/doi.org\/10.1056\/nejmoa1910038.","journal-title":"N Engl J Med"},{"key":"8148_CR13","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2967\/jnumed.112.114298","volume":"54","author":"KK Wong","year":"2013","unstructured":"Wong KK, Piert M. Dynamic bone imaging with 99mTc-labeled diphosphonates and 18F-NaF: mechanisms and applications. J Nucl Med. 2013;54:590\u20139. https:\/\/doi.org\/10.2967\/jnumed.112.114298.","journal-title":"J Nucl Med"},{"key":"8148_CR14","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00330-018-5682-x","volume":"29","author":"E Dyrberg","year":"2018","unstructured":"Dyrberg E, Hendel HW, Huynh THV, Klausen TW, L\u00f8gager VB, Madsen C, et al. 68Ga-PSMA-PET\/CT in comparison with 18F-fluoride-PET\/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol. 2018;29:1221\u201330. https:\/\/doi.org\/10.1007\/s00330-018-5682-x.","journal-title":"Eur Radiol"},{"key":"8148_CR15","first-page":"287","volume":"47","author":"E Even-Sapir","year":"2006","unstructured":"Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT, 18F-Fluoride PET, and 18F-Fluoride PET\/CT. J Nucl Med. 2006;47:287\u201397.","journal-title":"J Nucl Med"},{"key":"8148_CR16","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7:1635\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771.","journal-title":"JAMA Oncol"},{"key":"8148_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40644-020-0290-9","volume":"20","author":"LJ Petersen","year":"2020","unstructured":"Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging. 2020;20:1\u20138. https:\/\/doi.org\/10.1186\/s40644-020-0290-9.","journal-title":"Cancer Imaging"},{"key":"8148_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00850-y","author":"A Mari","year":"2025","unstructured":"Mari A, Cadenar A, Giudici S, Cianchi G, Albisinni S, Autorino R, et al. A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET\/CT in the initial staging of prostate cancer. Prostate Cancer Prostatic Dis. 2025. https:\/\/doi.org\/10.1038\/s41391-024-00850-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"8148_CR19","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.2967\/jnumed.122.265205","volume":"64","author":"MJ Hagens","year":"2023","unstructured":"Hagens MJ, Luining WI, Jager A, Donswijk ML, Cheung Z, Wondergem M, et al. The diagnostic value of PSMA PET\/CT in men with newly diagnosed unfavorable intermediate-risk prostate cancer. J Nucl Med. 2023;64:1238\u201343. https:\/\/doi.org\/10.2967\/jnumed.122.265205.","journal-title":"J Nucl Med"},{"key":"8148_CR20","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, Fornarini G, Cioffi M, Laudicella R, et al. The homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging. 2024;51:3753\u201364. https:\/\/doi.org\/10.1007\/s00259-024-06797-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8148_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bju.14828","volume":"124","author":"JW Yaxley","year":"2019","unstructured":"Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, et al. Risk of metastatic disease on 68gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124:401\u20137. https:\/\/doi.org\/10.1111\/bju.14828.","journal-title":"BJU Int"},{"key":"8148_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur Urol. 2023;84:36\u201348. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.001.","journal-title":"Eur Urol"},{"key":"8148_CR23","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.2967\/jnumed.125.270822","volume":"66","author":"C Madsen","year":"2025","unstructured":"Madsen C, Zacho HD, Fugl\u00f8 D, Nielsen K, Kongsted P, Bisbjerg R, et al. 18F-PSMA PET\/CT Versus 18F-NaF PET\/CT for staging and treating newly diagnosed high-risk prostate cancer: a prospective single-center study. J Nucl Med. 2025;66:1898\u2013902. https:\/\/doi.org\/10.2967\/jnumed.125.270822.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08148-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08148-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08148-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:32Z","timestamp":1793672972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08148-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8148"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08148-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"1 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is an observational study. A waiver of informed consent was granted by the local health authorities (ID 19085433). The study was registered with and approved by the Danish Data Protection Agency (journal no. P-2019\u2013729) and conducted in compliance with the General Data Protection Regulation.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}